20 results about "Acyl transferase" patented technology

Provided are a preparation method for alpha-amino acid ester acyl transferase, and a use thereof in dipeptide synthesis. A method for dipeptide synthesis comprises: using alpha-amino acid ester acyl transferase to perform a dipeptide synthesis reaction, to obtain a dipeptide; the alpha-amino acid ester acyl transferase has a conserved region with an amino acid sequence as shown in SEQ ID NO: 1. Using the alpha-amino acid ester acyl transferase, a variety of functional dipeptides can be synthesized, a substrate spectrum is wide, and the synthesis efficiency of some enzymes is high; this can be well used for industrial amplification, with low cost and high yield, thus realizing green chemistry.

The invention relates to a diacylglycerol acyltransferase capable of synthesizing triglyceride as well as a coding gene and application of the diacylglycerol acyltransferase, and belongs to the field of enzymology, the nucleotide sequence of the gene for coding the diacylglycerol acyltransferase is as shown in SEQ ID NO.1, and the amino acid sequence of the diacylglycerol acyltransferase is as shown in SEQ ID NO.2. The invention also provides a recombinant plasmid and a recombinant engineering bacterium containing the gene of the enzyme. Diglyceride and an acyl donor are used as substrates, and triglyceride is catalytically synthesized through an acyl transfer reaction by using the enzyme. The invention provides an efficient tool for realizing enzymatic biosynthesis and large-scale production of natural triglyceride.

The invention relates to the technical field of microorganisms, and particularly discloses a recombinant microorganism and application thereof in production of hexamethylenediamine. Compared with an original strain, the recombinant microorganism disclosed by the invention expresses a carboxylic acid reductase CAR variant, a CAR activating enzyme sfp and putrescine transaminase patA; the amino acid sequence of the carboxylic acid reductase CAR variant is as shown in SEQ ID NO. 28; preferably, adipic acid transporters DcaK and DcaP, acyl CoA transferases DcaI and DcaJ, an acylated succinate semialdehyde dehydrogenase sucD, and a 4-aminobutyric acid transaminase gabT are also expressed. By utilizing the recombinant microorganism, 6-aminocaproic acid / adipic acid can be efficiently converted into hexamethylenediamine, and a new method is provided for green biosynthesis of hexamethylenediamine.

The invention discloses application of a histone acetyltransferase inhibitor in preparation of a medicine for improving liver fatty degeneration. The invention discloses application of a histone acetyltransferase inhibitor for selectively inhibiting Gcn5 acetylation of histone H3 in preparation of drugs for treating and / or preventing diseases caused by liver fatty degeneration. And the histone acetyltransferase inhibitor for selectively inhibiting acetylation of Gcn5 on histone H3 is CPTH2. The compound CPTH2 reduces the protein abundance of a liver lipid synthesis transcription factor SREBP1c by inhibiting the acetylation activity of H3K9 and H3K14, and obviously improves the liver fatty degeneration of C57BL / 6J mice fed with high fat diet.

The invention relates to a compound of formula (I): where A is an optionally substituted heteroaryl; useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The.invention also provides compositions comprising the compound for treating such disorders.

According to a first aspect, the invention relates to a pharmaceutical composition prepared for oral administration for the treatment of obesity, comprising an active ingredient which inhibits serine palmitoyltransferase (EC 2.1.3.50). Another aspect of the invention relates to the use of myriocin for the treatment of obesity.

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and n are defined as in claim 1, which are ghrelin O-acyl transferase (GOAT) inhibitors for use in the treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

Compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). Methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and / or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

The invention relates to a determination method of a male aging marker and a male aging clock, and belongs to the technical field of medical examination. A group of male senescence markers comprises a plurality of cell factors related to male senescence, and the cell factors comprise but are not limited to transforming growth factors b1, carcinoembryonic antigen related cell adhesion molecules 1, capillary morphogenetic genes 2, dipeptidyl peptidase IV, growth differentiation factors 15, hepatocyte adhesion molecules, L-selectin and neurogenic locus Notch homologous proteins 3. The kit comprises a total prostate specific antigen, a regenerated pancreas islet derived protein 4, alpha-N-acetylneuraminic acid alpha-2, 8-aminoacyltransferase 1, a thromboregulatory protein and a vascular endothelial growth factor receptor 3. The method has the advantages that a group of specific senescence markers related to male senescence are confirmed, a male cytokine senescence clock determination model is constructed, and the biological age of a male individual is evaluated and the senescence speed is predicted through quantitative analysis of the biomarkers.

The invention provides recombinant yarrowia lipolytica for producing beta-elemene in a subcellular compartment and a construction method and application of the recombinant yarrowia lipolytica, and belongs to the field of bioengineering. The recombinant yarrowia lipolytica is prepared by taking yarrowia lipolytica as an original strain, performing localization expression on a germacene A synthase coding gene in a liposome through a liposome localization signal Oleosin, and knocking out a peroxisome biogenic factor 10 in a yarrowia lipolytica genome, so as to obtain the recombinant yarrowia lipolytica. And inserting into a 3-hydroxy-3-methylglutaryl CoA reductase expression cassette, a farnesyl pyrophosphate synthase expression cassette, an isopentenyl pyrophosphate isomerase expression cassette, a diacylglycerol acyltransferase expression cassette and a sterol acyltransferase expression cassette to obtain the recombinant expression vector. The recombinant yarrowia lipolytica disclosed by the invention can be used for efficiently producing beta-elemene.

Embodiments of the present disclosure relate to methods and compositions associated with targeted cancer treatment, which are directed to specific terminal deoxynucleoside acyl transferase peptides associated with HLA-A02. In particular embodiments, cell therapies employ cells encoding chimeric T cell receptors that target peptides, and optionally bispecific T cell conjugates that target the same peptides. In particular embodiments, one or both are used to treat hematological malignancies.

This invention discloses a genetically engineered bacterium and its application in enhancing lactic acid production in *Escherichia coli*, belonging to the field of bioengineering. The genetically engineered bacterium of this invention uses *E. coli* as the starting strain and is obtained through genetic engineering operations. In this genetically engineered bacterium, the phosphoacetyltransferase-acetylkinase locus pta-ack and the alcohol dehydrogenase gene adhE are knocked out or deleted, while exogenous lactate dehydrogenase and exogenous monocarboxylic acid transporter genes are introduced and overexpressed. The modified genetically engineered bacterium, while retaining the advantages of *E. coli* such as easy culture and rapid growth rate, significantly improves the yield and conversion rate of lactic acid. Compared to the starting strain, the lactic acid concentration increases to 6 g / L with pta-ack knockout alone, and to 8 g / L with double knockout of pta-ack and adhE. Furthermore, the lactic acid concentration increases to approximately 20 g / L and 23 g / L with overexpression of exogenous lactate dehydrogenase and exogenous monocarboxylic acid transporter, respectively.

The invention belongs to the technical field of biological medicine and functional food, and discloses a fermentation composition based on signal peptide induction, which is prepared by the following steps: step 1, mixing astragalus membranaceus, lotus leaf, poria cocos and pericarpium citri reticulatae according to the mass ratio of (3-5): (2-4): (2-3): (1-2) to prepare a compound raw material; the fermentation composition is remarkable in effect and multi-target, the food intake can be reduced by reducing mRNA expression of hypothalamus neuropeptide Y and rat-related peptide and increasing the content of glucagon-like peptide-1, lipid metabolism can be regulated and controlled by improving mRNA expression of liver farnesoid X receptors, AMP-dependent protein kinase and carnitine palmitoyl transferase-1, and the food intake can be reduced by increasing the content of glucagon-like peptide-1. The abundance of intestinal bifidobacteria can be improved, and the expression of brown fat heat production related genes is promoted to balance intestinal flora; the safety of the composition is subjected to dual verification of animal and crowd tests, the weight and blood fat indexes of obese rats and obese crowds are remarkably improved, and the liver and kidney functions are not damaged.

Compounds of Formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof are provided, which are DGAT2 inhibitors. Also provided are methods of preparing the compounds of Formula I, pharmaceutical compositions comprising the compounds of Formula I, and use of these compounds in the treatment of liver steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, type 2 diabetes, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, reduced cognitive ability, dementia, heart and kidney disease ( The present invention relates to methods for treating chronic kidney disease and heart failure, such as chronic kidney disease and heart failure, and related diseases and disorders, comprising administering to a patient in need thereof a compound of Formula I. # imgabs0 #

The present invention provides a galactose-1-phosphate uridyl transferase mutant and its use in producing L-lysine. This galactose-1-phosphate uridyl transferase comprises the following A1) or A2): A1) a protein having the amino acid sequence set forth in SEQ ID NO: 2, and A2) a fusion protein in which a tag is linked to the N-terminus and / or C-terminus of A1). The present invention has discovered that the amount of L-lysine produced in cells can be increased by terminating or knocking out the gene encoding galactose-1-phosphate uridyl transferase in advance. L-lysine can be produced by mutating or knocking out the gene encoding galactose-1-phosphate uridyl acyl transferase in cells. The present invention has excellent applicability.

The present invention relates to compounds of general formula I,wherein the groups R1, R2 and n are defined herein, which are ghrelin O-acyl transferase (GOAT) inhibitors. The invention also relates to the use of compounds of formula (I) for treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

The invention discloses a (4-N, N-disubstituted amino) phenyl carboxylic acid compound as well as a preparation method and application thereof, the compound can be used as a palmitoyl transferase inhibitor, and by inhibiting palmitoyl transferase, the palmitoylation process of substrate protein is further inhibited, and the inhibition effect on tumor cells is exerted. Experiments show that the compounds have different degrees of anti-proliferative activity to different cancer cells and different degrees of enzyme inhibition activity to palmitoyl transferase, most of the compounds have better inhibition activity to cancer cells and palmitoyl transferase than positive control drugs, and the compounds can be used for development of new-generation antitumor drugs.

The present disclosure provides compounds of Formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. The present disclosure also provides methods of preparing the compounds of Formula I, pharmaceutical compositions comprising the compounds of formula I and the use of these compounds in the treatment of hepatic steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, type 2 diabetes, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, decline in cognitive ability, dementia, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, and the like. Methods of treating heart and kidney diseases, such as chronic kidney disease and heart failure, and related diseases and disorders, comprising administering to a patient in need thereof a compound of Formula I. # imgabs0 #

The present application relates to a kind of cancer immunotherapy polypeptide and application, disclose a kind of targeting PD-L1 lactylation modified treatment peptide, its preparation method and application in tumor immunotherapy drug, the treatment peptide amino acid sequence as shown in SEQ ID NO.3.The present application is based on the lactylation modification mechanism of PD-L1, according to the interaction region of lactoyltransferase HAT1 and PD-L1 design the treatment peptide, it can significantly reduce the interaction of HAT1 and PD-L1, reduce the lactylation level of PD-L1;The treatment peptide is combined with PD-1 antibody can further inhibit tumor growth, improve the immunotherapy effect of PD-1 antibody, suitable for the immunotherapy of ovarian cancer, lung cancer and other tumors.The present application provides new ideas and effective means for the immunological checkpoint therapy with PD-L1 as target, solves the technical problem of low objective response rate of existing PD-1 / PD-L1 inhibitor.